Strategic Growth Allergan (Forest Laboratories) operates in pharmaceutical manufacturing with a sizable global footprint and multi-billion revenue potential, indicating opportunities for high-value partnerships, OEM relationships, or distribution deals across markets.

Product Expansion Recent and ongoing product launches such as Latisse and TissuGlu, plus a focus on aesthetics and eye care, create cross-sell potential for complementary devices, formulations, or services within a connected care ecosystem.

M&A Backdrop Allergan’s acquisition history by AbbVie and subsequent strategic shifts suggest openness to collaborations, licensing, or co-development arrangements with pharma and biotech firms to accelerate portfolio growth.

Regulatory & recalls Past regulatory actions and recalls in the broader Allergan portfolio highlight a need for robust quality assurance, risk management, and compliance solutions, offering services to strengthen manufacturing and product safety practices.

Digital & Analytics A tech stack leveraging cloud platforms and analytics tools indicates readiness for data-driven partnerships, including digital marketing optimization, patient insights, and operational efficiency enhancements.